Alnylam Pharmaceuticals (ALNY) Share-based Compensation Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.73% |
| Dec 31, 2025 | 15.88% |
| Sep 30, 2025 | 23.76% |
| Jun 30, 2025 | 27.04% |
| Mar 31, 2025 | 10.40% |
| Dec 31, 2024 | 6.72% |
| Sep 30, 2024 | -0.09% |
| Jun 30, 2024 | 23.88% |
| Mar 31, 2024 | 7.20% |
| Dec 31, 2023 | 8.47% |
| Sep 30, 2023 | 6.91% |
| Jun 30, 2023 | 27.79% |
| Mar 31, 2023 | 15.32% |
| Sep 30, 2022 | 63.80% |
| Jun 30, 2022 | 18.12% |
| Mar 31, 2022 | 13.26% |
| Dec 31, 2021 | 16.64% |
| Sep 30, 2021 | 29.00% |
| Jun 30, 2021 | 28.16% |
| Mar 31, 2021 | 18.85% |
| Dec 31, 2020 | 17.17% |
| Sep 30, 2020 | 46.54% |
| Jun 30, 2020 | 52.97% |
| Mar 31, 2020 | 33.23% |
| Dec 31, 2019 | 37.56% |
| Sep 30, 2019 | 78.05% |
| Jun 30, 2019 | 64.29% |
| Mar 31, 2019 | 41.78% |
| Dec 31, 2018 | 38.92% |
| Sep 30, 2018 | 46.41% |
| Jun 30, 2018 | 58.84% |
| Mar 31, 2018 | 44.81% |
| Sep 30, 2017 | 26.26% |
| Jun 30, 2017 | 33.75% |
| Mar 31, 2017 | 37.86% |
| Dec 31, 2016 | 38.30% |
| Sep 30, 2016 | 17.01% |
| Jun 30, 2016 | 17.10% |
| Mar 31, 2016 | 41.62% |
| Dec 31, 2015 | 28.13% |
| Sep 30, 2015 | 4.10% |
| Jun 30, 2015 | -4.48% |
| Mar 31, 2015 | 9.11% |
| Dec 31, 2014 | 27.81% |
| Sep 30, 2014 | -14.52% |